The increased expression level of PD-L1 in immune cells has been reported to be linked with a higher response rate to ICIs and better prognosis in several cancers, including urothelial carcinoma (62), Hence, PD-L1 could be applied in effective cancer immunotherapy strategies. The gene discussed is CD274; the disease is urothelial carcinoma.